Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Glykämische Kontrolle und Variabilität mit verschiedenen kommerziell verfügbaren Hybrid-Closed-Loop-Systemen bei Menschen mit Typ-1-Diabetes: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Diabetes, Obesity and Metabolism · 2026-01 · 28 (S1) · 3-12
DOI: 10.1111/dom.70150 ↗Auf einen Blick
37 RCTs zeigen unterschiedliche CGM-Metriken und HbA1c-Werte zwischen kommerziellen HCL-Systemen bei Typ-1-Diabetes. Die Ergebnisse variierten nach Altersgruppe und System.
Fragestellung
Wie unterscheiden sich kommerzielle Hybrid-Closed-Loop-Systeme in glykämischer Kontrolle und Variabilität bei Menschen mit Typ-1-Diabetes?
Methode
Systematische Übersicht mit Metaanalyse von RCTs; Suche in vier Online-Datenbanken und Handsuche von Kongressberichten bis 18. April 2025.
Ergebnisse
37 Studien zu 7 HCL-Systemen. <18 Jahre: TIR 64,1 % (95 %-KI 61–67,2); 59,3 % mit MiniMed 780G bis 68 % mit Control IQ. ≥18 Jahre: TIR 70,8 % (95 %-KI 68,6–73); 63,1 % mit Omnipod 5 bis 74,4 % mit MiniMed 780G.
Schlussfolgerung der Autor:innen
In RCTs zeigen kommerzielle HCL-Systeme unterschiedliche Ergebnisse bei CGM-Metriken und HbA1c bei Menschen mit Typ-1-Diabetes.
Kernaussagen
- 37 RCTs mit 7 kommerziellen HCL-Systemen
- TIR und HbA1c variierten je nach System und Altersgruppe
- Jüngere und erwachsene Gruppen zeigten unterschiedliche Werte
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 29.09.2025. Verfasst von Sergio Di Molfetta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, University Hospital "Consorziale Policlinico" of Bari, Bari, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glycemic Control, Insulin Infusion Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medtronic.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To provide an updated analysis of the performance of different hybrid closed loop (HCL) systems in randomised controlled trials (RCTs) on subjects with type 1 diabetes. Materials and methods We conducted a systematic review with meta‐analysis. We searched four online databases and performed hand‐searching of conference proceedings to find studies from inception to 18 April 2025. We included RCTs enrolling subjects with type 1 diabetes, evaluating commercial HCL systems against other insulin therapy regimens, with a duration of intervention ≥2 weeks, and reporting time in range (TIR) as an outcome. Studies involving pregnant women were excluded.
Results
A total of 37 studies evaluating seven different HCL systems (CamAPS Fx, Control IQ, DBLG1, iLet BP, MiniMed 670G, MiniMed 780G, and Omnipod 5) were included. In studies with a mean age < 18 years, mean TIR was 64.1% (95% CI: 61‐67.2), ranging from 59.3% (95% CI: 49.6‐69.1) with MiniMed 780G to 68% (95% CI: 65.8‐70.3) with Control IQ, and end‐of‐study HbA1c was 7.4% (95% CI: 7‐7.7), ranging from 6.7% (95% CI: 6.6‐6.9) with CamAPS Fx to 7.9% (95% CI: 6.9‐9) with MiniMed 780G. In studies with a mean age ≥ 18 years, mean TIR was 70.8% (95% CI: 68.6‐73), ranging from 63.1% (95% CI: 59.4‐66.8) with Omnipod 5 to 74.4% (95% CI: 69.7‐79.1) with MiniMed 780G, and end‐of‐study HbA1c was 7.1% (95% CI: 7‐7.3), ranging from 7.0% (95% CI: 6.9‐7.1) with Control IQ to 7.2% (95% CI: 7‐7.5) with MiniMed 670G.
Conclusions
In RCTs, commercial HCL systems show different achievements of CGM metrics and HbA1c in people with type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, University Hospital "Consorziale Policlinico" of Bari, Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
- Endocrinology Unit, Regional General Hospital "Francesco Miulli", Bari, Italy.
- Interdisciplinary Department of Medicine, Hygiene Section, University of Bari Aldo Moro, Bari, Italy.
- Section of Endocrinology, Department of Medicine and Surgery, Libera Università Mediterranea (LUM) University, Bari, Italy.
ORCID-Profile: Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Mariangela Caporusso, Paolo Trerotoli, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
Förderung
- Medtronic
Zitieren
APA
Di Molfetta, S., Di Gioia, L., Caruso, I., Caporusso, M., Trerotoli, P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2026). Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 28(S1), 3-12. https://doi.org/10.1111/dom.70150
Vancouver
Di Molfetta S, Di Gioia L, Caruso I, Caporusso M, Trerotoli P, Natalicchio A, et al. Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2026;28(S1):3-12. doi:10.1111/dom.70150
BibTeX
@article{DiMolfetta2026,
author = {Di Molfetta, Sergio and Di Gioia, Ludovico and Caruso, Irene and Caporusso, Mariangela and Trerotoli, Paolo and Natalicchio, Annalisa and Perrini, Sebastio and Laviola, Luigi and Giorgino, Francesco},
title = {Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {S1},
pages = {3--12},
doi = {10.1111/dom.70150}
}
EUVIMED